LUND, Sweden, Feb. 26, 2021 /PRNewswire/
-- Immunovia AB (publ) ("Immunovia") today published two
new data sets in scientific poster formats, including results from
the development phase of the Company's IMMray™ PanCan-d blood based
test for early detection of pancreatic cancer. The posters present
the scientific data from the Optimization Study and the Commercial
Test Model Study (CTMS) and demonstrate test performance for the
different clinical indications. The posters can be found following
this link to the company's home page:
https://immunovia.com/media/publications/immray-pancan-d/
For more information, please contact:
Patrik Dahlen, CEO, Immunovia
Email: patrik.dahlen@immunovia.com
Tel: +46 73 376 76 64
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently in the final validation phase. The company aims for a
sales start at the end of Q1 2021 with subsequent commercial
testing in Q2.
When validated, IMMray™ PanCan-d will be the first blood-based
test for early diagnosis of pancreatic cancer on the market, with a
potential to significantly improve patient survival and
outcome.
Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and
Lund, Sweden will provide
laboratory testing services in two accredited reference
laboratories.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia-publishes-data-sets-on-the-optimization-study-and-commercial-test-model-study,c3297079
The following files are available for download:
https://mb.cision.com/Main/13121/3297079/1379967.pdf
|
Press release
(PDF)
|